Beijing Tropical Medicine Research Institute, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, P.R. China.
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 21205, USA.
BMC Microbiol. 2020 Apr 10;20(1):87. doi: 10.1186/s12866-020-01777-9.
Bartonella henselae is a Gram-negative bacterium transmitted to humans by a scratch from cat in the presence of ectoparasites. Humans infected with B. henselae can result in various clinical diseases including local lymphadenopathy and more serious systemic disease such as persistent bacteremia and endocarditis. The current treatment of persistent B. henselae infections is not very effective and remains a challenge. To find more effective treatments for persistent and biofilm Bartonella infections, in this study, we evaluated a panel of drugs and drug combinations based on the current treatment and also promising hits identified from a recent drug screen against stationary phase and biofilm recovered cells of B. henselae.
We evaluated 14 antibiotics and 25 antibiotic combinations for activity against stationary phase B. henselae (all antibiotics were at 5 μg/ml) and found that ciprofloxacin, gentamicin, and nitrofurantoin were the most active agents, while clofazimine and miconazole had poor activity. Drug combinations azithromycin/ciprofloxacin, azithromycin/methylene blue, rifampin/ciprofloxacin, and rifampin/methylene blue could rapidly kill stationary phase B. henselae with no detectable CFU after 1-day exposure. Methylene blue and rifampin were the most active agents against the biofilm B. henselae after 6 days of drug exposure. Antibiotic combinations (azithromycin/ciprofloxacin, azithromycin/methylene blue, rifampin/ciprofloxacin, rifampin/methylene blue) completely eradicated the biofilm B. henselae after treatment for 6 days.
These findings may facilitate development of more effective treatment of persistent Bartonella infections in the future.
巴尔通体(Bartonella henselae)是一种革兰氏阴性菌,通过带有寄生虫的猫抓伤将其传播给人类。感染巴尔通体(B. henselae)的人类可能导致各种临床疾病,包括局部淋巴结病和更严重的全身性疾病,如持续性菌血症和心内膜炎。目前对持续性巴尔通体(B. henselae)感染的治疗效果并不十分有效,仍然是一个挑战。为了找到更有效的治疗持续性和生物膜巴尔通体感染的方法,在这项研究中,我们评估了一组基于当前治疗方案的药物和药物组合,以及最近针对静止期和生物膜回收细胞的巴尔通体(B. henselae)药物筛选中确定的有前途的药物。
我们评估了 14 种抗生素和 25 种抗生素组合对静止期巴尔通体(所有抗生素均为 5μg/ml)的活性,发现环丙沙星、庆大霉素和呋喃妥因是最有效的药物,而氯法齐明和咪康唑活性较差。药物组合阿奇霉素/环丙沙星、阿奇霉素/亚甲蓝、利福平/环丙沙星和利福平/亚甲蓝可以在 1 天暴露后迅速杀死静止期巴尔通体(B. henselae),没有可检测到的 CFU。亚甲蓝和利福平是 6 天药物暴露后最有效的抗生物膜巴尔通体药物。抗生素组合(阿奇霉素/环丙沙星、阿奇霉素/亚甲蓝、利福平/环丙沙星、利福平/亚甲蓝)在治疗 6 天后完全清除了生物膜巴尔通体(B. henselae)。
这些发现可能有助于未来开发更有效的持续性巴尔通体感染治疗方法。